Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PAHC
Previous Symbol
CUSIPN/A
Phone201-329-7300
Debt
Debt-to-Equity Ratio1.62
Current Ratio3.26
Quick Ratio1.82
Price-To-Earnings
Trailing P/E Ratio18.94
Forward P/E Ratio19.16
P/E Growth2.82
Sales & Book Value
Annual Sales$820 million
Price / Sales1.62
Cash Flow$2.4371 per share
Price / Cash Flow13.52
Book Value$4.58 per share
Price / Book7.19
Profitability
EPS (Most Recent Fiscal Year)$1.74
Net Income$64.88 million
Net Margins7.89%
Return on Equity38.91%
Return on Assets10.60%
Miscellaneous
Employees1,500
Outstanding Shares40,380,000
Market Cap$1.33 billion
OptionableOptionable
Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions
What is Phibro Animal Health's stock symbol?
Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."
How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?
Phibro Animal Health declared a quarterly dividend on Tuesday, November 6th. Stockholders of record on Wednesday, November 28th will be given a dividend of $0.12 per share on Wednesday, December 19th. This represents a $0.48 annualized dividend and a dividend yield of 1.46%. The ex-dividend date of this dividend is Tuesday, November 27th. This is a boost from Phibro Animal Health's previous quarterly dividend of $0.10. View Phibro Animal Health's Dividend History.
How were Phibro Animal Health's earnings last quarter?
Phibro Animal Health Corp (NASDAQ:PAHC) released its earnings results on Tuesday, November, 6th. The company reported $0.39 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.42 by $0.03. The company had revenue of $200.20 million for the quarter, compared to analyst estimates of $203.99 million. Phibro Animal Health had a net margin of 7.89% and a return on equity of 38.91%. Phibro Animal Health's quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the business posted $0.38 earnings per share. View Phibro Animal Health's Earnings History.
When is Phibro Animal Health's next earnings date?
What guidance has Phibro Animal Health issued on next quarter's earnings?
Phibro Animal Health updated its FY19 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $1.68-1.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.75. Phibro Animal Health also updated its FY 2019 guidance to $1.68-1.72 EPS.
What price target have analysts set for PAHC?
3 brokers have issued 1-year price objectives for Phibro Animal Health's shares. Their forecasts range from $33.00 to $46.00. On average, they anticipate Phibro Animal Health's share price to reach $40.3333 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.
What is the consensus analysts' recommendation for Phibro Animal Health?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings and 1 hold rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Phibro Animal Health.
Has Phibro Animal Health been receiving favorable news coverage?
News coverage about PAHC stock has trended somewhat positive on Saturday, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Phibro Animal Health earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Phibro Animal Health's key competitors?
Some companies that are related to Phibro Animal Health include Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Array Biopharma (ARRY), FibroGen (FGEN), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT) and Emergent Biosolutions (EBS).
Who are Phibro Animal Health's key executives?
Phibro Animal Health's management team includes the folowing people:
- Mr. Jack Clifford Bendheim, Chairman, Pres & CEO (Age 71)
- Mr. Larry L. Miller, Chief Operating Officer (Age 54)
- Mr. Dean J. Warras, Pres of Animal Health & Nutrition - North America (Age 49)
- Mr. Richard G. Johnson, Chief Financial Officer (Age 69)
- Mr. Thomas G. Dagger, Sr. VP, Gen. Counsel & Corp. Sec. (Age 60)
Who are Phibro Animal Health's major shareholders?
Phibro Animal Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.61%), Vanguard Group Inc (5.14%), Vanguard Group Inc. (5.14%), Ceredex Value Advisors LLC (2.10%), Renaissance Technologies LLC (1.99%) and Dimensional Fund Advisors LP (1.27%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel A Welch, Daniel M Bendheim, Dean J Warras, Gerald K Carlson, Jack Bendheim, Larry Lee Miller, Richard G Johnson and Thomas G Dagger. View Institutional Ownership Trends for Phibro Animal Health.
Which institutional investors are selling Phibro Animal Health stock?
PAHC stock was sold by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, Panagora Asset Management Inc., Polaris Capital Management LLC, Seizert Capital Partners LLC, Allianz Asset Management GmbH, S. Muoio & CO. LLC, U S Global Investors Inc and Prudential Financial Inc.. Company insiders that have sold Phibro Animal Health company stock in the last year include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, Jack Bendheim and Larry Lee Miller. View Insider Buying and Selling for Phibro Animal Health.
Which institutional investors are buying Phibro Animal Health stock?
PAHC stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Renaissance Technologies LLC, JPMorgan Chase & Co., Assenagon Asset Management S.A., Acadian Asset Management LLC, Eagle Asset Management Inc. and Confluence Investment Management LLC. View Insider Buying and Selling for Phibro Animal Health.
How do I buy shares of Phibro Animal Health?
Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Phibro Animal Health's stock price today?
One share of PAHC stock can currently be purchased for approximately $32.95.
How big of a company is Phibro Animal Health?
Phibro Animal Health has a market capitalization of $1.33 billion and generates $820 million in revenue each year. The company earns $64.88 million in net income (profit) each year or $1.74 on an earnings per share basis. Phibro Animal Health employs 1,500 workers across the globe.
What is Phibro Animal Health's official website?
How can I contact Phibro Animal Health?
Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]
MarketBeat Community Rating for Phibro Animal Health (NASDAQ PAHC)
MarketBeat's community ratings are surveys of what our community members think about Phibro Animal Health and other stocks. Vote "Outperform" if you believe PAHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
